Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial

2019163 citationsJournal Articlebronze Open Access

Authors

NCT02499770.

Good health and well-being

Published in: Annals of Oncology

Volume 30, Issue 10, pp. 1613-1621

Field-Weighted Citation Impact: 8.38